Lapatinib Teva

Lapatinib, the active ingredient in Lapatinib Teva, is a Tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats HER2‑positive breast cancer in adult patients, targeting the EGFR/HER1 and HER2 pathways that drive tumor growth.

GNH USA supplies Lapatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lapatinib is a targeted therapy that acts on HER2‑driven malignancies. - HER2‑positive metastatic breast cancer: used in combination with other agents to delay disease progression. - HER2‑positive locally advanced breast cancer: administered when disease is not amenable to curative surgery. - HER2‑positive gastric or gastro‑oesophageal adenocarcinoma: employed as part of combination regimens to improve clinical outcomes.

Lapatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: watery stools occurring in many patients. - Rash: skin eruptions, often on the trunk or extremities. - Nausea: mild to moderate feeling of stomach upset. - Fatigue: generalized tiredness affecting daily activities. - Stomatitis: inflammation or ulceration of the mouth lining. - Elevated liver enzymes: increased ALT/AST on laboratory testing.

Serious or Rare Side Effects: - Cardiac dysfunction: reduced left ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: clinically significant liver injury. - Interstitial lung disease: non‑infectious pulmonary inflammation.

Patients receiving Lapatinib should be monitored for specific safety considerations. - Cardiac monitoring: assess left ventricular function before and during therapy. - Liver function: perform baseline and periodic ALT/AST tests. - Skin assessment: watch for severe rash or mucosal involvement. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lapatinib interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase exposure and toxicity. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Digoxin: possible increase in serum concentrations, observe for toxicity. - Other HER‑targeted agents: additive cardiac risk, evaluate cardiac function regularly.